Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Taro Pharmaceutical Industries Ltd | TARO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
42.42 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 27.37 - 45.76 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 42.42 | USD |
Taro Pharmaceutical Industries Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.59B | 37.58M | - | 572.95M | 25.45M | 0.68 | 62.65 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Taro Pharmaceutical Indu... News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TARO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 42.60 | 42.70 | 42.24 | 42.44 | 22,781 | -0.18 | -0.42% |
1 Month | 41.94 | 42.70 | 41.85 | 42.31 | 24,716 | 0.48 | 1.14% |
3 Months | 42.45 | 42.70 | 40.45 | 42.09 | 42,185 | -0.03 | -0.07% |
6 Months | 34.61 | 45.76 | 33.88 | 41.54 | 42,140 | 7.81 | 22.57% |
1 Year | 27.55 | 45.76 | 27.37 | 39.21 | 45,478 | 14.87 | 53.97% |
3 Years | 74.88 | 76.00 | 22.89 | 41.74 | 28,279 | -32.46 | -43.35% |
5 Years | 104.32 | 106.48 | 22.89 | 60.54 | 34,976 | -61.90 | -59.34% |
Taro Pharmaceutical Indu... Description
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada, Israel, and Other Countries. |